Hepatitis D News Today

Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.

The effectiveness of the engineered investigational human monoclonal antibody VIR-3434 in inhibiting viral spread in hepatitis B and D viruses demonstrated.

New study reveals that Hepatitis D is zoonotic and came from America. This finding could help explain the sudden outbreak of the disease globally.

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute

1. In this randomized controlled trial, 48 weeks of buleviritide treatment resulted in reduced hepatitis D ribonucleic acid (RNA) levels in patients with chronic hepatitis D. 2. The buleviritide group also had lower alanine transaminase (ALT) levels as compared to controls. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis D virus (HDV) is an RNA

World Hepatitis Day is an opportunity to remind people of the impact of viral hepatitis and to offer information that can help prevent, diagnose, and treat these diseases, said one expert.

There is no approved treatment for chronic hepatitis D virus infection in the United States, but recent phase 3 trial results showed encouraging safety and efficacy associated with bulevirtide.

Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients.

Contrary to previous assumptions, hepatitis D virus-like agents seem to be active in a range of different animal species, from fish all the way to termites.

In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV).